Amgen’s Repatha Achieves Landmark Results in Phase 3 VESALIUS-CV Trial, Significantly Reducing Cardiovascular Events in High-Risk Patients Without Prior Heart Attack or Stroke
Reuters
Oct 02
Amgen's Repatha Achieves Landmark Results in Phase 3 VESALIUS-CV Trial, Significantly Reducing Cardiovascular Events in High-Risk Patients Without Prior Heart Attack or Stroke
Amgen Inc. has announced that its Phase 3 VESALIUS-CV clinical trial met its dual primary endpoints, demonstrating that Repatha® (evolocumab) significantly reduced the risk of major adverse cardiovascular events $(MACE)$ in individuals without a prior history of heart attack or stroke. The trial enrolled over 12,000 high-risk patients, most of whom were on high-intensity or moderate LDL-cholesterol lowering therapy, and followed them for a median of approximately 4.5 years. The primary endpoints included time to first occurrence of a composite of coronary heart disease death, heart attack, or ischemic stroke, as well as time to first occurrence of these events or any ischemia-driven arterial revascularization. The results were both statistically and clinically significant, with no new safety signals observed. These findings have already been announced by the company.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amgen Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA89193) on October 02, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.